IRIDEX (NASDAQ:IRIX) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued on Tuesday. The firm set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Performance

NASDAQ:IRIX opened at $0.95 on Tuesday. The company has a 50-day moving average of $1.42 and a 200-day moving average of $1.61. The firm has a market cap of $15.80 million, a price-to-earnings ratio of -1.42 and a beta of 0.94. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55. IRIDEX has a twelve month low of $0.78 and a twelve month high of $3.65.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.